Evidence map›Paper›PMID 39687393›Full record

ArticleERJ open research2024

Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease.

Linh T Ngo, Michaella J Rekowski, Devin C Koestler, Takafumi Yorozuya, Atsushi Saito, Imaan Azeem, Alexis Harrison, M Kristen Demoruelle, Jonathan Boomer, Bryant R England and 8 more

Abstract read
In one paragraph

Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2024
    Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Linh T NgoDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Michaella J RekowskiDepartment of Cancer Biology, University of Kansas School of Medicine, Kansas City, KS, USA.ORCID https://orcid.org/0000-0003-3132-6380
Devin C KoestlerDepartment of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Takafumi YorozuyaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan.
Atsushi SaitoDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan.
Imaan AzeemDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Alexis HarrisonDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
M Kristen DemoruelleDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, USA.
Jonathan BoomerDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Bryant R EnglandDivision of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.
Paul WoltersDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.
Philip L MolyneauxNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-1301-8800
Mario CastroDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Joyce S LeeDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO, USA.
Joshua J SolomonDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health Hospital, Denver, CO, USA.
Koji KoronumaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan.
Michael P WashburnDepartment of Cancer Biology, University of Kansas School of Medicine, Kansas City, KS, USA.ORCID https://orcid.org/0000-0001-7568-2585
Scott M MatsonDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5M
NCI NIH HHS P30 CA168524NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

Background: Idiopathic interstitial pneumonias (IIPs), such as idiopathic pulmonary fibrosis and interstitial pneumonia with autoimmune features, present diagnostic and therapeutic challenges due to their heterogeneous nature. This study aimed to identify intrinsic molecular signatures within the lung microenvironment of these IIPs through proteomic analysis of bronchoalveolar lavage fluid (BALF). Methods: Patients with IIP (n=23) underwent comprehensive clinical evaluation including pre-treatment bronchoscopy and were compared with controls without lung disease (n=5). Proteomic profiling of BALF was conducted using label-free quantitative methods. Unsupervised cluster analyses identified protein expression profiles that were then analysed to predict survival outcomes and investigate associated pathways. Results: Proteomic profiling successfully differentiated IIP from controls. k-means clustering based on protein expression revealed three distinct IIP clusters, which were not associated with age, smoking history, or baseline pulmonary function. These clusters had unique survival trajectories and provided more accurate survival predictions than the Gender Age Physiology index (concordance index 0.794 Conclusions: The unsupervised clustering of BALF proteomics provided a novel stratification of IIP patients, with potential implications for prognostic and therapeutic targeting. The identified molecular phenotypes underscore the diversity within the IIP classification and the potential importance of personalised treatments for these conditions. Future validation in larger, multi-ethnic cohorts is essential to confirm these findings and to explore their utility in clinical decision-making for patients with IIP.

Identifiers

PMID39687393
PMCPMC11647942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.